The Readout Loud

336 Episodes

1. 314: JD Vance's biotech ties, Cassava resignations, and insulin shortages

   Published: 7/18/2024
2. 313: Biotech layoffs, founder-focused VC, & a big pharma exit

   Published: 7/11/2024
3. 312: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate

   Published: 6/27/2024
4. 311: Fauci's memoir, Alnylam's tenuous trial, and a mid-year review

   Published: 6/20/2024
5. 310: Duchenne gene therapy setback, Alzheimer's drug endorsement & why a STAT reporter buys weed (for journalism)

   Published: 6/13/2024
6. 309: Psychedelics at the FDA, ASCO recap, & MorphoSys update

   Published: 6/6/2024
7. 308: An ASCO preview & another Duchenne trial failure

   Published: 5/30/2024
8. 307: More tumult at BIO & coercive care for sickle cell patients

   Published: 5/23/2024
9. 306: Live! From the STAT Breakthrough Summit West

   Published: 5/16/2024
10. 305: Everything you need to know about H5N1 bird flu

    Published: 5/9/2024
11. 304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

    Published: 5/2/2024
12. 303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

    Published: 4/18/2024
13. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

    Published: 4/11/2024
14. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

    Published: 4/4/2024
15. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

    Published: 3/28/2024
16. 299: Live! From the STAT Breakthrough Summit East

    Published: 3/21/2024
17. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    Published: 3/14/2024
18. 297: VC turmoil, GLP-1 competition, & the war on recovery

    Published: 3/7/2024
19. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

    Published: 2/29/2024
20. 295: Humira’s legacy, CEO symbolism, and genomic surgery

    Published: 2/22/2024